| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2.6B | ¥2.5B | +3.0% |
| Operating Income | ¥-5.1B | ¥-3.8B | -36.5% |
| Ordinary Income | ¥-5.1B | ¥-3.7B | -37.2% |
| Net Income | ¥-5.1B | ¥-3.7B | -37.3% |
| ROE | -19.0% | -11.6% | - |
Stellapharma Corporation FY2026 Q3 cumulative results show revenue of 2.6 billion yen (YoY +3.0%), operating loss of 5.1 billion yen (YoY deterioration of 36.5%), ordinary loss of 5.1 billion yen (YoY deterioration of 37.2%), and net loss of 5.1 billion yen (YoY deterioration of 37.3%). Despite a high gross profit margin of 86.6%, the company faces severe profitability challenges with selling, general and administrative expenses of 7.4 billion yen significantly exceeding total revenue. Total assets declined to 47.8 billion yen from 54.2 billion yen, while equity decreased to 26.9 billion yen from 32.1 billion yen as accumulated losses expanded. Cash reserves remain substantial at 26.9 billion yen, providing near-term liquidity buffer, though the structural imbalance between revenue scale and fixed costs presents fundamental operational challenges requiring immediate attention.
Revenue increased modestly by 3.0% YoY to 2.6 billion yen, driven by continued product sales though at limited scale. Cost of revenue was 0.3 billion yen, resulting in gross profit of 2.3 billion yen and maintaining an exceptionally high gross margin of 86.6%, indicating strong pricing power or high-value product characteristics. However, selling, general and administrative expenses totaled 7.4 billion yen, representing approximately 283% of revenue and creating the primary driver of operating losses. This cost structure suggests significant fixed overhead related to research and development activities, regulatory compliance, or infrastructure maintenance typical of pharmaceutical development companies. The operating loss expanded from 3.8 billion yen to 5.1 billion yen YoY, a 36.5% deterioration reflecting both the modest revenue growth insufficient to cover expenses and potential increases in period costs. Non-operating income and expenses contributed a small net gain of 0.02 billion yen, having minimal impact on ordinary income which stood at negative 5.1 billion yen. The gap between ordinary income and net income was negligible, indicating absence of material extraordinary items or tax effects. The company exhibits a revenue up, profit down pattern, though calling it profit down understates the severity given the deepening losses. The fundamental issue is a mismatch between revenue generation capacity and cost base, where even with strong gross margins, the absolute revenue level cannot support the operational infrastructure required for pharmaceutical development and commercialization activities.
[Profitability] Operating margin of negative 196.2% reflects the severe structural imbalance between revenue scale and cost base, deteriorating from already negative levels in prior periods. Net profit margin stands at negative 196.2%, driven by selling, general and administrative expenses of 7.4 billion yen against revenue of only 2.6 billion yen. Return on equity calculated at negative 19.0%, with this metric driven primarily by the substantial net losses rather than capital efficiency issues. Return on assets at negative 10.7% indicates poor asset utilization in generating earnings, though the company maintains significant cash reserves. [Cash Quality] Cash and deposits total 26.9 billion yen, representing 56.3% of total assets and providing substantial liquidity cushion. Current assets of 46.4 billion yen cover current liabilities of 2.5 billion yen by a factor of 18.7 times, indicating extremely strong short-term debt coverage capacity. [Investment Efficiency] Asset turnover of 0.055 indicates very low revenue generation per unit of assets, reflecting the capital-intensive nature and early-stage development profile typical of pharmaceutical companies. Working capital management shows concerning signs with work-in-process inventory of 11.0 billion yen representing an unusually high proportion of current assets. [Financial Health] Equity ratio of 56.4% remains relatively healthy, though declining from 59.2% in the prior period as losses erode retained earnings. Current ratio of 1872.1% demonstrates exceptional liquidity position. Interest-bearing debt totals 6.3 billion yen in long-term borrowings with debt-to-equity ratio of 0.23, maintaining conservative leverage. Retained earnings deteriorated significantly to negative 5.1 billion yen from negative 1.4 billion yen, reflecting accumulated losses though not yet threatening capital adequacy.
Cash and deposits increased from prior period levels to 26.9 billion yen, providing substantial liquidity despite ongoing operational losses, suggesting either proceeds from prior financing activities or drawdown of existing cash reserves at a measured pace. The current quarter's net loss of 5.1 billion yen implies cash consumption from operations, though the remaining cash position of 26.9 billion yen provides coverage for approximately 5 quarters at current burn rates before additional financing would be required. Working capital components show concerning trends with work-in-process inventory at 11.0 billion yen indicating potential inefficiencies in production planning or prolonged development timelines characteristic of pharmaceutical research. Accounts receivable of 5.7 billion yen relative to quarterly revenue of 2.6 billion yen suggests extended collection periods requiring monitoring. Current liabilities remain minimal at 2.5 billion yen, indicating the company maintains clean payment practices with suppliers and short-term creditors. The combination of high cash reserves and low current liabilities results in a short-term liquidity coverage ratio of 10.8 times, providing substantial financial flexibility for ongoing operations despite the operating losses.
Ordinary income of negative 5.1 billion yen versus operating income of negative 5.1 billion yen shows minimal contribution from non-operating activities, with the non-operating net balance adding only 0.02 billion yen. Non-operating income consists primarily of interest income and other financial gains typical of cash-rich balance sheets, representing less than 1% of revenue scale and having no material impact on overall earnings profile. The absence of significant non-operating gains or losses indicates earnings are driven almost entirely by core operational factors rather than financial engineering or one-time items. Operating losses derive from the fundamental business model challenge of high fixed costs against limited revenue scale, representing a structural rather than temporary earnings quality issue. Without operating cash flow disclosure for the quarterly period, direct assessment of cash-backed earnings is limited, though the continuation of substantial cash reserves despite ongoing losses suggests either strong historical cash generation, prior capital raises, or measured deployment of existing resources. The high gross margin of 86.6% indicates strong unit economics at the product level, suggesting earnings quality concerns stem from scale and overhead management rather than core product profitability.
Full-year guidance projects revenue of 377 million yen, representing a 60.7% decline YoY, operating loss of 922 million yen, ordinary loss of 908 million yen, and net loss of 911 million yen. Current Q3 cumulative results show revenue of 2.6 billion yen against full-year guidance of 377 million yen, indicating actual results have already exceeded full-year projections by a factor of approximately 7 times, suggesting either the guidance reflects a different fiscal period structure or represents a significant revision from prior expectations. Operating loss of 5.1 billion yen cumulative through Q3 substantially exceeds the full-year guidance of 922 million yen in loss magnitude, indicating either the guidance has not been updated to reflect current trajectories or represents management's expectation of significant improvement in Q4. The substantial variance between cumulative results and full-year guidance warrants clarification, as a 691% revenue achievement rate and operating loss exceeding guidance by over 5 times suggests either a timing mismatch in reporting periods or material changes in business outlook requiring formal revision. The dividend forecast remains zero for both interim and year-end periods, consistent with the loss-making status and capital preservation priorities.
Annual dividend stands at zero yen for both second quarter and fiscal year-end, unchanged from prior periods. No dividend payout reflects the company's loss-making status with accumulated deficit of 5.1 billion yen, making distribution of earnings impossible under retained earnings constraints. Payout ratio is not applicable given negative net income. No share buyback activities are disclosed during the period. Total return ratio remains zero as the company retains all resources for operational funding and loss coverage. The zero distribution policy appears appropriate given the structural operating losses and need to preserve capital for ongoing pharmaceutical development and commercialization activities. Dividend resumption would require sustained return to profitability and rebuilding of distributable retained earnings, which under current trajectories remains a longer-term consideration pending successful cost rationalization and revenue scaling initiatives.
The primary risk factor is the structural cost base misalignment where selling, general and administrative expenses of 7.4 billion yen significantly exceed revenue of 2.6 billion yen, requiring either dramatic revenue scaling or substantial cost reduction to achieve profitability. The revenue trajectory guidance suggesting 60.7% YoY decline creates uncertainty around commercial execution and market demand sustainability, posing risks to both near-term financial performance and longer-term business viability. Working capital management concerns including work-in-process inventory of 11.0 billion yen representing 90.5% of total inventory and extended accounts receivable collection periods indicate operational inefficiencies that tie up capital and may signal underlying issues in production planning, demand forecasting, or customer credit quality requiring immediate management attention to prevent further cash consumption acceleration.
[Industry Position] (Reference - Proprietary Analysis) Within the pharmaceutical industry peer group, Stellapharma's financial profile reflects characteristics common to early-stage or development-focused pharmaceutical companies. Operating margin of negative 196.2% compares to an industry median of negative 218.2%, positioning the company slightly better than the median peer though still deeply unprofitable. Net profit margin of negative 196.2% versus industry median of negative 216.8% shows similar relative positioning. Revenue growth of positive 3.0% significantly outperforms the industry median of negative 12.5%, indicating relatively stable commercial traction despite limited scale. Return on equity of negative 19.0% compares favorably to industry median of negative 35.8%, reflecting less severe profitability challenges or better capital structure relative to peers. Equity ratio of 56.4% sits below the industry median of 67.8%, suggesting somewhat higher leverage though still maintaining conservative balance sheet positioning. Current ratio of 1872.1% far exceeds industry median of 6.62 times, indicating exceptional liquidity management relative to peers. Asset turnover of 0.055 trails the industry median of 0.17, reflecting lower revenue generation efficiency per unit of asset base. The company's financial profile suggests it operates as a development-stage pharmaceutical entity with better-than-peer revenue stability and liquidity positioning, though sharing the sector-typical characteristics of negative operating margins and low asset turnover common to pre-profitability pharmaceutical businesses. (Industry: Pharmaceutical companies, N=13, Comparison: 2025-Q3 period, Source: Proprietary analysis)
First, the company maintains exceptionally strong liquidity with cash and deposits of 26.9 billion yen covering current liabilities by 18.7 times, providing substantial runway for continued operations despite ongoing losses and reducing near-term financial distress risk, though the quarterly burn rate of approximately 5 billion yen implies this buffer may last roughly 5 quarters absent revenue improvement or cost reduction initiatives. Second, the fundamental business model challenge of 7.4 billion yen in operating expenses against 2.6 billion yen in revenue represents the critical factor requiring resolution, with the high 86.6% gross margin indicating strong unit economics that suggest profitability is achievable through either revenue scaling by approximately 3 times at current margins or meaningful expense rationalization while maintaining commercial capabilities. Third, the significant variance between Q3 cumulative results and full-year guidance requires clarification to assess management's visibility into business trajectories, as current results show both higher revenue and larger losses than implied by guidance, suggesting either reporting period misalignment or material business developments warranting updated forecasts and enhanced disclosure around the drivers of expected Q4 performance.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.